Mofezolac

Mofezolac is an inhibitor of COX-1 (IC50 = 14 nM). It is selective for COX-1 over COX-2 (IC50 = 440 nM). Mofezolac (1 µg/ml) protects against LPS-induced cell death in BV-2 microglia. In vivo, mofezolac (6 mg/kg, i.p.) reduces hippocampal microglial activation and prostaglandin E2 (PGE2, Cay-14010) production in a mouse model of LPS-induced neuroinflammation. It reduces phenylquinone-induced writhing in a mouse model of acute pain. Dietary administration of mofezolac (1,200 ppm) reduces the number of aberrant crypt foci and tumors in a rat model of beef tallow diet-induced colon carcinogenesis.Formal Name: 3,4-bis(4-methoxyphenyl)-5-isoxazoleacetic acid. CAS Number: 78967-07-4. Synonyms: N-22. Molecular Formula: C19H17NO5. Formula Weight: 339.3. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: soluble. lambdamax: 232 nm. SMILES: COC1=CC=C(C=C1)C2=C(CC(O)=O)ON=C2C3=CC=C(OC)C=C3. InChi Code: InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22). InChi Key: DJEIHHYCDCTAAH-UHFFFAOYSA-N.